



National Brain Tumor Society

2025 ANNUAL REPORT

# Letter to the Community

**Dear NBTS Community,**

As we mark the midpoint of this decade, we are filled with gratitude for the unwavering dedication of the donors, volunteers, advocates, and partners who **fuel this movement**.

Your generosity has led us to a historic first in neuro-oncology — our community saw another new FDA drug approval this year — marking the first time we've seen drug approvals for brain tumors two years in a row. The FDA-granted accelerated approval of dordaviprone (Modeyso) for recurrent H3K27M-mutant diffuse midline glioma (DMG) offers a foothold of hope for pediatric and adult patients with this tumor type, and the back-to-back drug approvals demonstrate momentum in the field like we've never seen before.

Thanks to your support, the National Brain Tumor Society added to this momentum by awarding \$2.6 million in grants to researchers in 2025, and investing \$500K into promising new drugs and treatments through the Brain Tumor Investment Fund. Grant and investment funding helped propel current and future clinical trials in multiple tumor types in adults and pediatrics, and advanced research to improve a variety of therapeutic treatments, including immunotherapy, DNA Damage Response, precision medicine, medical devices, and more.

After a proposed 40% cut to federal research funding, NBTS advocates and the greater cancer community pushed back, resulting in far fewer funding cuts than initially anticipated. Bolstered by our advocates at events like May's Head to the Hill and July's Glioblastoma Awareness Day, as well as consistent pressure from NBTS's local advocates, Congress called for an increase in cancer funding in 2026, including for brain tumor research. We also helped reintroduce and advance the bipartisan, NBTS-authored BRAIN Act, which would increase funding for brain tumor research and scale efforts to help patients better connect to clinical trials.

And because of your support this year, NBTS helped 48% more individual members of the brain tumor community than the prior year, reflecting the growing reach of our one-on-one guidance for those seeking resources and support. We also expanded our MyTumorID® campaign, designed to improve the likelihood of biomarker testing and clinical trial participation through patient-ready information for people with a brain tumor, their care partners, and providers. The NBTS community came together across the country in a variety of ways, from walks, rides, races, and golf outings to collaborative think-tank meetings. Our Research Roundtable meeting convened the FDA, NIH, life sciences companies, academic research leaders, patients, and advocates to discuss how we can make real progress over the rest of the decade.


As we look ahead, we are committed to innovating in research methods, particularly amid rapid technological advancement, and to ensuring that the lived experiences of patients and care partners are incorporated into research. We will continue to be the community that comes together so that no one needs to face this disease alone.

With your support, we will keep this momentum going — to inspire hope, to ensure a better quality of life for those experiencing this devastating disease, and to find better treatments and, ultimately, a cure.

**Leah Recht**  
NBTS Board Chair



**David F. Arons**  
President & Chief Executive Officer



# Mission, Vision, and Values



## MISSION

National Brain Tumor Society unrelentingly invests in, mobilizes, and unites our community to discover a cure, deliver effective treatments, and advocate for patients and care partners.

## VISION

Conquering and curing brain tumors — once and for all.

## VALUES

- Patients First
- Best-In-Class Science and Service to Our Community
- Relentlessly Results Driven
- Constructive, Candid, and Transparent
- Committed to Public Trust
- Collaborative and Inclusive
- Strengthened by Diversity, Equity, Inclusion, and Belonging
- Positive (Can-Do) Attitude



## DEFEAT

We drive and influence best-in-class medical research to develop and deliver new innovative treatments and potential cures to patients with brain tumors as quickly as possible.



## CONNECT

We convene, educate, and unite the brain tumor community.



## CHANGE

We fuel the voice and power of the brain tumor community to advocate and influence public policy.

*Featured on the front cover: Adam and Whitney Hayden in 2018*



“As much as this adventure was difficult, it nowhere near compares to what my brother Matt and other brain tumor survivors experience on a daily basis. We must continue to fight for more funding to improve research on the care and treatment of brain tumors.”

— Ryan D., *Hikers for Hope*

# NBTS Accelerates Pediatric and Young Adult Breakthroughs

For the second year in a row, the National Brain Tumor Society (NBTS) and the greater brain tumor community saw a new drug approval by the FDA that will benefit adult and pediatric patients with specific malignant brain tumors. These approvals continue to underscore the importance of identifying and developing drugs that target the molecular abnormalities responsible for brain tumors.

## FDA approves first-ever drug to treat recurrent H3K27M-mutant diffuse midline glioma



The U.S. Food and Drug Administration (FDA) granted accelerated approval to dordaviprone (Modeyso), formerly known as ONC201, manufactured by Jazz Pharmaceuticals, Inc., as the first and only treatment for recurrent H3K27M-mutant **diffuse midline glioma** (DMG) — a rare, aggressive brain tumor that predominantly affects children and young adults.

This approval marks a milestone in the treatment landscape for one of the most devastating diagnoses a family can face. DMG patients have historically had few treatment options, and this new approval offers a measure of hope and foothold for these underserved patients and their families.

NBTS played multiple roles in advancing this discovery alongside the drug's previous developers, Oncoceutics and then Chimerix, including funding that helped advance foundational research and drug development of ONC201.

## NBTS's DNA Damage Response Consortium (DDR-C) is advancing research that could improve survival and quality of life for pediatric patients with brain tumors

Among the promising therapeutic approaches on the DDR-C's radar is AZD1390, a drug that targets a protein called ATM, which helps tumor cells repair DNA damage caused by radiation therapy. When radiation damages tumor cell DNA, ATM acts as a kind of repair mechanism, allowing cells to survive and the tumor to keep growing. Blocking ATM, researchers hypothesized, could make radiation significantly more effective.

That hypothesis got a meaningful boost when researchers at St. Jude Children's Research Hospital, including scientists who are now members of the DDR-C, published findings showing that combining AZD1390 with radiation showed promise against **diffuse midline gliomas** (DMG), a highly aggressive pediatric brain tumor that includes a subset called **diffuse intrinsic pontine gliomas** (DIPG). NBTS funding supported that work.

Those findings have since contributed to the launch of a Children's Oncology Group phase I clinical trial at multiple U.S. sites, evaluating the safety and optimal dosing of AZD1390 in combination with radiation in pediatric patients with high-grade glioma. Radiation remains the only therapy that consistently prolongs life for patients with DMG and DIPG, and it is hoped that inhibiting the tumor's ability to repair DNA damage may help patients live longer.

## DDR-C FAST FACTS

8  
world-class  
institutions

7  
published papers

34  
drugs qualified

2  
associated  
clinical trials

2  
clinical trials in  
development

8  
active industry  
collaborations

# NBTS Advances Innovative Brain Tumor Research

National Brain Tumor Society (NBTS) drives and influences best-in-class medical research to develop and deliver new innovative treatments and potential cures to patients with brain tumors as quickly as possible.

## NBTS-funded discovery drives new glioblastoma clinical trial

Researchers at UCLA, with the support of NBTS, identified a critical vulnerability in **glioblastoma** (GBM) that renders it resistant to treatment.

The researchers analyzed more than 50 patient tumor samples using two powerful techniques called genetic sequencing and functional testing to identify how GBMs resist therapy. They found that most tumors rely on two key proteins — MCL-1 and BCL-XL — that act like protective shields, blocking the signals that normally trigger cancer cell death. Importantly, the researchers discovered that standard treatments such as radiation or chemotherapy weaken MCL-1, which leaves the tumor increasingly dependent on BCL-XL as a final survival mechanism. Thus, specifically targeting BCL-XL in this context may remove the tumor's last line of defense, thereby rendering it susceptible to the signals triggering cancer cell death.

This discovery has now advanced to an active phase I clinical trial led by investigators at Memorial Sloan Kettering Cancer Center. The trial is evaluating ABBV-155 and ABBV-637, antibody-drug conjugates (ADCs) designed to deliver cancer-killing drugs directly to glioblastoma cells, either alone or in combination with other therapies, including a drug called KTM-101. In preclinical models, both ABBV-155 and ABBV-637 demonstrated effective anti-tumor activity, reducing tumor size and improving survival, especially when combined with radiation or a drug targeting alterations in the EGFR gene.

NBTS played a key role in advancing this work from early discovery to clinical testing. In partnership with StacheStrong, NBTS supported research that identified the BCL-XL vulnerability and the potential of the ADCs, ABBV-155 and ABBV-637, against GBMs. NBTS also previously funded early work on KTM-101 (formerly ERAS-801) through the Sharpe-NBTS Brain Cancer Research Awards program.

Subsequent funding from the Department of Defense Peer-Reviewed Cancer Research Program, which NBTS actively advocates for every year, also helped propel this research forward. These combined efforts demonstrate how strategic funding and advocacy can help bridge the gap between laboratory discovery and promising new treatment opportunities for patients.

“The findings provide a clear path toward developing targeted, patient-specific therapies that could significantly improve outcomes for patients diagnosed with glioblastoma.”

— TIMOTHY CLOUGHESY, MD,  
University of California, Los Angeles



## DID YOU KNOW?



NBTS awarded \$2.6 million in grant dollars to researchers in 2025.



In 2025, NBTS funded research across many tumor types, including but not limited to astrocytoma, atypical teratoid rhabdoid tumors (AT/RT), craniopharyngioma, diffuse midline gliomas (DMG/ DIPG), embryonal tumors, ependymoma, glioblastoma, medulloblastoma, meningioma, metastatic brain tumors, and oligodendroglioma.



NBTS funded 26 named principal investigators across 17 health institutions in 2025.

# CERN Funds Cutting-Edge Ependymoma Research

The Collaborative Ependymoma Research Network (CERN) Foundation, a designated program of the National Brain Tumor Society, works to advance ependymoma research toward developing new and better treatments for this rare brain and spinal cord tumor that affects both adults and children.

## NBTS-awarded fellowship focuses on mRNA vaccine work for pediatric brain tumor

In 2024, Dr. Samreen Shaikh, from the University of Queensland's Ian Frazer Centre for Children's Immunotherapy Research, received a two-year CERN and Robert Connor Dawes (RCD) Scientific Fellowship designed to accelerate the formation of Australia's first ependymoma-focused research team. Her fellowship goal was to develop and test an RNA vaccine against **recurrent ependymomas**.

To achieve this goal, Dr. Shaikh traveled to the Fred Hutchinson Cancer Center in Seattle, Washington. Under

the expert mentorship of Eric Holland, MD, PhD, she acquired key laboratory skills that were critical to the project's success. Specifically, she learned how to create, maintain, and use validated ependymoma animal models.

Dr. Shaikh is now equipped with the requisite tools for assessing the vaccine in preclinical models of ependymoma. In addition, the Australian-based research team has partnered with an international mRNA vaccine company to manufacture the vaccine and generate the safety data required for translation to a phase I clinical trial.

“Dr. Holland is the leading expert in brain cancer research, and learning from him has been an invaluable experience that will significantly advance my research. This expertise, which isn't currently available in Australia, is essential to our understanding in developing an mRNA vaccine for ependymoma, and CERN made this opportunity possible. With his expertise now combined with ours, we can advance the effort to bring mRNA vaccine for brain cancer into the clinic at a much faster pace than otherwise would be possible, all thanks to the support of NBTS and the CERN Foundation.” — DR. SAMREEN SHAIKH



## CERN advances research to improve care and diagnosis for spinal ependymoma

Ependymoma is a rare tumor of the brain and spinal cord that affects both children and adults. While **spinal ependymomas** generally have a favorable five-year survival rate, these statistics don't capture the wide variation in patients' post-treatment experiences. Some individuals remain stable for periods, while others experience repeated recurrences, leading to progressive neurological impairment, chronic pain, or disease spread. These differing outcomes — particularly in the myxopapillary subgroup — are likely driven by subtle biological differences that can't be identified under a microscope.

To better understand these differences, CERN has funded Eric Holland, MD, PhD, at Fred Hutchinson Cancer Center to analyze spinal ependymoma tumor samples at the molecular level using RNA sequencing. This research aims

to identify previously unrecognized subgroups or further refine current existing classifications.

Improved classification of spinal ependymomas will help researchers develop more targeted treatment approaches and optimize patient care. CERN-supported research has already led to key discoveries in ependymoma biology and the development of a molecular classification system. As new tools and insights emerge, these systems continue to evolve. This project seeks to further refine the classification of spinal ependymomas to ultimately improve treatment strategies and patient outcomes.



▲ Eric Holland, MD, PhD, Fred Hutchinson Cancer Center

# Brain Tumor Investment Fund® Fuels Innovative Treatment Development

The Brain Tumor Investment Fund (BTIF), an affiliate of the National Brain Tumor Society, is a venture philanthropy fund supporting NBTS's vision to conquer and cure brain tumors by investing in biotechnology, pharmaceutical, and medical device companies to catalyze new and novel treatments.

## BTIF accelerates phase II clinical trial evaluating a promising new vaccine to treat glioblastoma

In early 2025, the Brain Tumor Investment Fund invested in Diakonon Oncology, a company with a promising therapeutic vaccine, DOC1021, also known as dubodencel. Dubodencel is a dendritic cell vaccine, which is created using the patient's own dendritic cells that have been engineered to recognize their tumor as virally-infected and thus activate an immune response that targets and kills these cells. Their phase I trial showed overall positive immune responses and improved survival after treatment.

The BTIF investment, alongside additional financing, helped to accelerate the company's phase II **glioblastoma** clinical trial, which opened in 2025 with eight sites and will eventually include 20 centers across the country.

“With our phase II glioblastoma trial underway at leading treatment centers across the U.S., the financing comes at a critical inflection point as we begin defining the path toward commercialization.”

— JAY HARTENBACH,  
President and Chief Operating Officer,  
Diakonon Oncology

## BTIF funding supports a phase IIb study evaluating sonodynamic therapy to treat newly diagnosed glioblastoma

NBTS's Brain Tumor Investment Fund reinvested in Alpheus Medical in 2025 to support the company's work developing sonodynamic therapy for brain cancer. This innovative non-invasive approach to treatment uses ultrasound waves — without the need for imaging or sedation — to help a drug that targets and kills tumor cells.

This investment will help the company run a phase IIb randomized controlled clinical trial in patients with **newly diagnosed glioblastoma** in 2026.

VIEW THE  
**BRAIN TUMOR  
INVESTMENT  
FUND**  
PORTFOLIO  
ONLINE

“With support from the Brain Tumor Investment Fund, we are poised to generate pivotal evidence that could help establish a new standard of care for newly diagnosed brain tumors. This investment is a key inflection point for Alpheus and the glioblastoma community, advancing sonodynamic therapy from promise to clinical validation.”

— VIJAY AGARWAL, MD,  
FAANS, FCNS, President and CEO of Alpheus Medical

Connect with BTIF on LinkedIn:

 Brain Tumor Investment Fund

# NBTS Convenes Stakeholders to Advance Research

National Brain Tumor Society (NBTS) brings stakeholders together, including the Food and Drug Administration (FDA), National Institutes of Health (NIH), biopharmaceutical companies both large and small, researchers, medical providers, other brain tumor organizations, and patients and care partners, to foster discussion and take unified action.

## NBTS advances the only brain tumor-specific research advocate training program in the U.S.

In 2025, NBTS expanded its Brain Tumor Research Advocate program — the only one of its kind in the brain tumor space — by adding a new real-time research review element that allows trained advocates to provide immediate input on emerging studies in a one-hour research review session moderated by NBTS.


During the rapid-style session, researchers virtually present their research projects and engage in an open discussion with the trained advocates. This forum provides the researcher with a patient-focused perspective in real-time, which can be used to help shape research topics, questions, or strategies.

NBTS graduated its first class of research advocates at the end of 2025 and has recruited a second class. NBTS accepted 21 applicants for the second cohort of the Brain Tumor Research Advocate Program. Selected applicants included a range of experiences — a balance of patients and care partners across brain tumor types, ages, and geographic regions.

“

I found it extremely valuable to present at a real-time research review session. At the most basic level, having patient and care partner advocate input on whether or not the research was worthwhile was very meaningful and inspiring. Also, the research can never be successful if the intervention and the methods are not acceptable to their subjects, so getting that expert perspective was necessary.”

— CAROLINE CROOMS, MD, MPH, Icahn School of Medicine at Mount Sinai



## NBTS convenes thought leaders to plan for the future of neuro-oncology therapy development

In July 2025, NBTS hosted and led an in-person Research Roundtable to assess progress in neuro-oncology and identify actionable outcomes that will propel the field forward to better treatments and quality of life for patients with brain tumors by 2030.

Through workshops and small group discussions, NBTS guided participants in identifying realistic, high-impact actions to overcome barriers and advance therapy development. Discussion from the roundtable will inform the crafting of a two-year plan for the program.

## NBTS supports \$1 million in grant funding focused on developing liquid biopsy technologies

Through the Brain Tumor Funders' Collaborative (BTFC), NBTS partnered with the American Brain Tumor Association, Brain Tumour Foundation of Canada, and the Pediatric Brain Tumor Foundation to award \$1 million in new grants. This funding supports two multi-institutional pediatric research teams — Ching Lau, MD, at Connecticut Children's Medical Center and Paul Northcott, PhD, at St. Jude Children's Research Hospital — focused on developing liquid biopsy technologies.



“I joined my first NBTS caregiver support group, and they were so welcoming. I can’t thank them enough for creating that safe space where we can talk and not feel judged. I cried for the first time. Being able to cry without even having to say anything was a highlight. In that moment, they understood and said, ‘We’re here for you.’” — Sarah A., daughter and caregiver

# NBTS Educates the Brain Tumor Community

## NBTS expands reach and impact of the MyTumorID® public health campaign

National Brain Tumor Society launched the MyTumorID campaign in 2024 as the first-ever public health campaign for the brain tumor community. The initiative aims to help patients with brain tumors and their care partners understand the importance of identifying tumor biomarkers and exploring treatment options, including clinical trials, to make informed decisions about their care.

In 2025, NBTS expanded its educational offerings to make critical information more accessible to the brain tumor community, including hosting two live webinars on biomarker testing and clinical trials that 825 people registered to attend. NBTS also created new materials in Spanish, new blog content, and an animated video explaining biomarker testing.

Additionally, NBTS worked with leaders in neuro-oncology to draft a [group biomarker letter](#) to equip providers with evidence-based rationale to advocate for timely and thorough tumor testing for their patients. The letter can be shared with administrators, insurance payers, and other medical colleagues.

# MyTumorID

**ID** my tumor's biomarkers.  
**ID** my treatment options.  
**I Decide.**

“Understanding your tumor at the molecular level might not change the diagnosis, but it can illuminate the best way forward. And sometimes, that illumination is the difference between feeling helpless and feeling equipped.”



— JOHNATHAN M.,  
*patient with glioblastoma*

The campaign was further amplified by the addition of five affiliate organizations — AANS-CNS Joint Section on Tumors, Dragon Master Initiative, Glioblastoma Research Organization, Head for the Cure Foundation, and the Pediatric Brain Tumor Foundation.

NBTS's blog offers educational content on a variety of topics important to the brain tumor community. In 2025, our blog addressed radiation therapy, awake craniotomies, managing fatigue, misunderstood benign tumors, seizures, how to talk to kids about a brain tumor diagnosis and treatment, and more. The blog also profiled individuals to help show others they are not alone in their brain tumor experience.

**READ  
THE  
LATEST**



▲ In this animated video, learn what biomarker testing is, why it's needed for a complete diagnosis, and why it's essential for making informed decisions about brain tumor treatment options.


# NBTS Delivers Personalized Support and Navigation

NBTS helps patients and care partners navigate their brain tumor experience through one-on-one support services.

In moments of crisis and uncertainty, patients, care partners, and loved ones turn to the National Brain Tumor Society's Personalized Support and Navigation team. Whether they're asking questions, searching for clinical trial information, or requesting resources as they navigate their next steps, NBTS meets them where they are.

This free program is designed to be responsive to the individual needs of the person asking for help — at the moment they reach out — and provide support, guidance, and resources to help them navigate a brain tumor diagnosis and throughout their experience.

In 2025, NBTS engaged **48% more patients and care partners** from across the country than last year, reflecting the growing reach and impact of our personalized support. Over the course of the year, the most navigated tumor types were glioblastoma, meningioma, and ependymoma.



“There were more questions than answers [after Mike's diagnosis], and that's when I got on the phone with this amazing person from NBTS. [Their Patient Navigator] was able to go over each line of the lab results that we had. She gave me a lot of questions to ask. She was able to put me in contact with some additional specialists. To date, they were the single biggest resource that I had.” — RACHEL L.

## FAST FACTS


745  
personalized  
navigation sessions

48%  
increase in  
engagement with  
patients and care  
partners

Top 3  
reasons for  
outreach were  
financial assistance  
information, clinical  
trial search, and  
information about  
second opinions


# NBTS Provides Support to the Brain Tumor Community

No one should have to face a brain tumor diagnosis alone. That's why the National Brain Tumor Society (NBTS) offers dedicated virtual spaces for patients, caregivers, and bereaved community members. In 2025, nearly 1,300 community members attended Brain Tumor Support Conversations, Caregiver Support Conversations, and Grief Support Conversations.



## **BRAIN TUMOR SUPPORT CONVERSATIONS**

"I just wanted to listen in my first meeting and see what other people are experiencing. They had the same type of feelings that I did." — *FRIDA A.*




## **CAREGIVER SUPPORT CONVERSATIONS**

"I didn't know what to expect my first night, but I already love this group. All of these descriptions really hit home. Isolating. Not fair. Mourning the loss of a previous life. Dark humor. All of it. I leave feeling more empowered. I am so glad I found this group and all of you." — *NICK S.*



## **GRIEF SUPPORT CONVERSATIONS**

"I think about the pain and hardship that this group/community has gone through, trying to figure out how to move on, but here we are again together another night. I think there is something to be said for that. I show up for myself, yes, but I am also here for you all." — *DAVE C.*



# NBTS Raises Brain Tumor Awareness

## DFW Brain Tumor Walk & Race ►

In March 2025, NBTS re-established its presence in North Texas with the DFW Brain Tumor Walk & Race at AT&T Stadium, home of the Dallas Cowboys. The event brought together patients, caregivers, and supporters from across the region to raise awareness and funds for the brain tumor community.



▲ *Senator Mark Kelly speaks at the reception.*

## ◀ Glioblastoma Awareness Day Reception

NBTS commemorated Glioblastoma Awareness Day — and concluded the year's annual nationwide awareness campaign — with an in-person reception on July 16, 2025, in Washington, D.C. Members of Congress, their staff, patients, care partners, and other members of the brain tumor community gathered to shine a spotlight on glioblastoma, the most common, complex, treatment-resistant, and deadliest type of brain cancer.

## Walt Disney World® Marathon Weekend ►

NBTS's Gray Nation Endurance® program added a new opportunity for runners to support the brain tumor community during the 2025 Walt Disney World® Marathon Weekend. Participants could take on the 5K, 10K, half or full marathon, or challenge themselves with Goofy's Race and a Half Challenge (half + full marathon) or the Dopey Challenge (all four distances). This year, 62 runners from 20 states joined the team to raise more than \$90,500 to fuel research, advocacy, and support for the brain tumor community.



## ◀ NASDAQ Bell Ringing

National Brain Tumor Society was honored to ring the NASDAQ closing bell alongside Innovate GBM and IQVIA to raise awareness for the glioblastoma community and everyone affected by brain tumors.



“It was really overwhelming to finish the National Brain Tumor Society’s DFW Brain Tumor Walk & Race and see my wife and son Barrett at the end. It felt like more than just finishing the 5K race. It felt like a huge victory over the brain tumor — almost more than the surgeries.” — *Michael K.*

# NBTS Champions Landmark Brain Tumor Bill

The Bolstering Research And Innovation Now (BRAIN) Act is the first piece of legislation that was developed specifically to meet the unique needs of brain tumor researchers, clinicians, patients, and survivors. This comprehensive, bipartisan bill spans the spectrum of policy hurdles from basic research, drug development, and clinical trials to awareness of critical treatment options, access to trials, and survivorship care.

## NBTS celebrates the reintroduction of the BRAIN Act

After its initial introduction with bipartisan support at the end of the 118th Congress, the National Brain Tumor Society (NBTS) worked with champions in Congress to strengthen and reintroduce the BRAIN Act (S.1330/H.R.2767) in April 2025. The BRAIN Act aims to advance the quest to defeat brain tumors, once and for all, by increasing research funding, fostering collaboration, promoting critical awareness efforts, and supporting innovations in and access to care.

Since then, NBTS and its advocates at the 2025 Head to the Hill and Advocate From Your State events have grown support for this bipartisan, bicameral legislation — NBTS’s signature policy priority — to more than 40 co-sponsors and improved its prospects for consideration in key committees.

## BRAIN Act Co-sponsors

### ORIGINAL CO-SPONSORS:

- Rep. Brian Fitzpatrick (R-PA)
- Rep. Lori Trahan (D-MA)
- Rep. Kim Schrier (D-WA)
- Rep. John Joyce (R-PA)
- Senator Richard Blumenthal (D-CT)
- Senator John Barrasso (R-WY)
- Senator Jack Reed (D-RI)
- Senator Mike Rounds (R-SD)

[CLICK HERE FOR FULL LIST OF SPONSORS](#)

Senator John Barrasso became one of the original co-sponsors of the BRAIN Act when it was first introduced in 2024 and then when it was reintroduced in 2025.

“I’m so grateful that he did that — for his wife, for my husband, and for the entire community,” said Tami A., who became an advocate after her husband Juel passed from glioblastoma. “This May, I was able to sit in his office in Washington, D.C., to discuss it, shake his hand, and tell him thank you in person. That was a real special moment.”



The BRAIN Act aims to advance the quest to defeat brain tumors by increasing research funding, fostering collaboration, promoting critical awareness efforts, and supporting innovations in and access to care.

“We’ve got some great support from Senator Barrasso and other key legislators,” Tami said. “I’m ready to be aggressive and fight alongside them. Let’s go and do something. It’s been too long without a change in the standard of care and treatment options, and we need to do better.”



▲ Tami, second from left, with Senator Barrasso, middle, alongside NBTS board members Frank Macchiarola, left, Chris Brown, second from right, and former board member Salo Zelmeyer, right, at the 2025 Head to the Hill.

# NBTS and Advocates Make an Impact

About 500 brain tumor community members, representing 46 states and Washington, D.C., advocated for the urgent, unmet needs of the brain tumor community at the National Brain Tumor Society's two signature advocacy events, Head to the Hill® and Advocate From Your State®.

## NBTS advocacy events set up early 2026 policy wins

Volunteer advocates from across the country united at Head to the Hill in Washington, D.C., in May to meet with their members of Congress and staff to push for increased brain tumor research funding and advocate for the support of the BRAIN Act.

In light of their advocacy, the Senate unanimously adopted two commemorative resolutions: Brain Tumor Awareness Month and Glioblastoma Awareness Day.

In September, community members participated in Advocate From Your State, where they held virtual meetings with their elected officials and staff to share their stories and address the challenges faced by those impacted by brain tumors, including pediatric patients and their families.

The stories shared at NBTS's two advocacy events were then amplified by nearly 2,000 additional advocates across the country, who sent over 5,000 emails to Congress.


These requests in 2025 for more medical research funding under the Department of Defense (DoD) and National Institutes of Health (NIH) positioned the community for an increase in brain tumor-related funding for FY26, including:

- Reinstatement of dedicated line-item funding for glioblastoma research under DoD
- Greater funding for Peer-Reviewed Cancer Research Program (PRCRP) within the DoD's Congressionally Directed Medical Research Program (CDMRP)

NBTS and advocates' efforts in 2025 also helped set the stage for the anticipated enactment in 2026 of critical childhood cancer bills — the Accelerating Kids' Access to Care (AKACA) Act and the Give Kids a Chance (GKAC) Act — and the extension of Medicare telehealth flexibilities.



*NBTS advocates gathered on the Capitol steps in D.C. to kick off the 15th annual Head to the Hill and listen to Congresswoman Lori Trahan and Representative Roger Williams talk about the importance of using their voices to advocate for the brain tumor community.*



**▲** *When she was in sixth grade, Rhea K. was diagnosed with pineoblastoma — a rare, cancerous brain tumor that forms in the pineal gland. She faced a recurrence shortly after getting her port removed from her first round of treatment. Now 23, Rhea shares her story and how she's using her voice to advocate for the pediatric brain tumor community.*

# NBTS Advocates Take Action to Create Change

National Brain Tumor Society, along with advocates across all 50 states and Washington, D.C., ensures the brain tumor community's needs are reflected in national medical research and health care policy.

## NBTS mobilizes a record number of advocates in 2025

More than 7,300 advocates took action on key policy issues by completing NBTS action alerts in record numbers. Three of this year's alerts ranked among the top five all-time, with some of the highest response rates ever seen at NBTS.

Together, advocates urged Congress to protect National Institutes of Health (NIH) funding for brain tumor research, pressed the National Cancer Institute (NCI) to reverse its decision to stop funding the Pediatric Brain Tumor Consortium, and advanced the policy priorities outlined in the NBTS advocacy events.

## NBTS spearheads a petition to protect vital funding and clinical trial opportunities for children with brain tumors

In late August, NBTS learned that the NCI made the decision to discontinue funding for the Pediatric Brain Tumor Consortium (PBTC), the agency's only program dedicated to early-phase clinical trials for children with brain tumors. The PBTC has played a pivotal role in advancing pediatric brain tumor treatment since its inception in 1999.


National Brain Tumor Society, in collaboration with nearly 4,500 advocates and nonprofit partners, sent a petition to reinforce with the NCI the critical function of the PBTC, to urge reinstatement of the program, and to underscore our community's expectations regarding continuity of services historically provided by the PBTC.

## FAST FACTS

1,792  
new advocates

16,434  
legislator connections

431  
meetings with Congress



▲ *Theo S. was diagnosed with medulloblastoma when he was just one year old. Five years later, Theo and his mom, Lori, began attending Head to the Hill.*

*Thirteen years post-diagnosis, Lori and Theo continue to go to Washington, D.C., to meet with other advocates from across the country and speak with their congressional representatives, sharing their story and pushing for the funding and research needed to find better treatments and, one day, a cure.*



“It’s important to support the National Brain Tumor Society because of the level of education and community building that they do. Funding gets things done, so we support NBTS for the research they fund and the advocacy they do to get federal research funding.”

— Katie N., oligodendroglioma caregiver



# Signature Events

## TOP FUNDRAISING INDIVIDUALS BY EVENT

Race For Hope DC:  
Kathy Savits - \$85,881

New England Brain Tumor Walk:  
Brett Johnson - \$35,917

National Brain Tumor Ride:  
Lisa Shapiro - \$29,412

Race For Hope Greater Philadelphia:  
Jeremy Toscano - \$22,421

Northern California Brain Tumor Walk:  
Leah Recht - \$18,902

Virginia Brain Tumor Walk & Race:  
Antonio Delgado - \$9,755

New York Brain Tumor Walk:  
Reid Alper - \$9,227

Southern California Brain Tumor Walk & Race:  
Roxy J. Striar - \$8,158

New Jersey Brain Tumor Walk:  
Sharon Polignano - \$8,172

Wisconsin Brain Tumor Walk & Race:  
Nicole Karimi - \$6,014

Georgia Brain Tumor Walk & Race:  
Robert Hernandez - \$5,902

Colorado Brain Tumor Walk & Race:  
Jayme Harker - \$5,030

DFW Brain Tumor Walk & Race:  
Taylor Durham - \$2,676

## TOP FUNDRAISING TEAMS: \$50,000+

Rachel's Racers: \$117,072


Lisa's Riders: \$90,444

ML's Milers: \$62,085

Rabbi's Runners: \$59,698



▲ “Being surrounded by other survivors and the energy of the event washed away the part of me that wanted to hide myself. That’s why the DFW Brain Tumor Walk & Race was such a turning point for me.” — Amber T., DFW Brain Tumor Walk & Race



▲ “Finding a cure, obviously, is the ultimate goal, because it’s personal. We have to live day to day. The team at NBTS allows me and my family to do that. It would be impossible without you guys.” — Rich P., National Brain Tumor Ride

# Signature Events

## TOP FUNDRAISING TEAMS: \$25,000+

DMG v. GBM: \$47,653

Team Oligo: \$45,070

Michelle's Pak: \$38,709

Smiley Strong: \$31,044

David Cook's Team for a Cure: \$30,038

Team E: \$28,356

Fiore's Fighting Force: \$27,525

Wendy's Quack Pack: \$27,263

Tori's Army: \$26,973

ReMARKable Strides: \$26,356

Maryland Brain Tumor Center: \$25,281



▲ “I attended the National Brain Tumor Society’s Northern California Brain Tumor Walk. For the first time since my glioblastoma diagnosis, I felt truly seen. Being surrounded by others who understood — families, survivors, friends — reminded me that even when life is uncertain, community is not.” — *Johnathan M., Northern California Brain Tumor Walk*

## TOP RECRUITING TEAMS

Ring the Bell for Matt — 131  
Race for Hope Greater Philadelphia

Tori's Army — 128  
Virginia Brain Tumor Walk & Race

Fiore's Fighting Force — 114  
New England Brain Tumor Walk

Rachel's Racers — 114  
Race for Hope DC

Neumer Tumor Troopers — 110  
Race for Hope DC

Team Incredibles — 92  
Race for Hope DC

Chrissy's Crusaders — 90  
Race for Hope Greater Philadelphia

Michelle's Pak — 90  
Race for Hope Greater Philadelphia

Team Stanford — 90  
Northern California Brain Tumor Walk

Alessia Strong — 88  
New York Brain Tumor Walk

**Our Top 10 individual fundraisers across all Signature Events raised over \$300,000 toward the National Brain Tumor Society's mission. Thank you to these amazing individuals for their fundraising efforts:**

- Kathy Savits
- Jonathan Weinberg
- Brett Johnson
- Lisa Shapiro
- Jeremy Toscano
- Sandra L. Kramer
- Cheri Mehigan Foley
- Leah Recht
- Bridget Hartman Basehoar
- Janet Almanza

# Fundraise Your Way

## \$100,000+

- McGuinness Memorial Golf Tournament by Brain Cancer Answer: \$144,104
- Shoals Concert for a Cure: \$135,782
- Fight for the Brain Happy Hour: \$122,567

## \$20,000+


- Remembering Patrick: \$70,287
- Capital Region Brain Tumor Walk for a Cure: \$70,151
- 7th Annual Childhood Brain Cancer Research Collaborative Golf Tournament: \$55,000
- Gunning for Glioblastoma: \$41,464
- Alston Construction Brain Tumor Awareness Month Fundraiser: \$39,720
- Chips for Kip Golf Tournament: \$33,000
- P&D Student Choreography Project: \$27,102
- Jones'n for a Cure Golf Tournament: \$25,000

## \$10,000+

- Michael Cassidy Shamrock 'N' Run: \$16,057
- Brain Tumor Awareness Walk on the Boardwalk: \$15,022
- St Vrain for the Brain 5K: \$15,001
- Anthony (A.) Paul Filiberto Art Sale: \$14,668
- Golf for Hope: \$14,371
- Gandython: \$12,404
- Harp's First Annual Joggin' for your Noggin 5K Fun Run/Walk: \$12,215
- Matt Shackelford Memorial Golf Tournament: \$12,086
- JC Shootout for Dreams Lacrosse Tournament: \$12,000
- Lisa Yarosz Invitational Golf Tournament: \$11,810
- Bags and Brews for Brains: \$11,559
- Joggin' 4 the Noggin 5K Run/Walk: \$11,250
- 50/31 Challenge: \$10,954
- Coaches Against Cancer: \$10,000
- Georgia Wireless Association David Downie Memorial Charity Golf Classic: \$10,000

## \$7,500+

- Wander to Wonder on Water: \$9,719
- Birdies for Brain Tumors: \$9,513
- Remembering Vicki Schaffer: \$9,146
- GOALS for GLIO: \$8,472
- Mimosa March To Cure Brain Cancer: \$8,470



▲ “[Hosting Fight for the Brain Happy Hour has] been one of the most meaningful things in my life. It’s meant a lot to my family. It’s meant so much to me. It’s been meaningful to the National Brain Tumor Society, and we really think it’s helped make a difference.”  
— Lido R., *Fight for the Brain Happy Hour*

► “Caring about the Zumba community and caring so much about wanting to make a difference in the brain tumor community, I combined the two and created a Zumbathon fundraiser. The support NBTS provides me to execute and successfully host GOALS for GLIO has made me feel a part of a family I didn’t know I needed.” — Felicia C., *GOALS for GLIO*



► “My family doesn’t want anybody else to go through what we are. We’re a very strong group of people, and we band together, and we will fight on behalf of the brain tumor community. What I take most pride in is giving the National Brain Tumor Society and the brain tumor community a platform.” — Erika P., *Gunning for Glioblastoma*



## FAST FACTS

**\$1.02 Million**  
raised through  
Fundraise Your Way events

**124**  
events took place in 2025

**35**  
states hosted Fundraise  
Your Way events

## \$20,000+

James Covey - Boston Marathon: \$67,804  
Amy Lentz - TCS New York City Marathon: \$52,045  
Sarah Augustine - Philadelphia Marathon: \$33,846  
Unbreakable Brooks - ASICS Falmouth Road Race: \$31,756  
Jolie Jimenez - Philadelphia Half Marathon: \$28,787  
Kristen Knowles - TCS New York City Marathon: \$27,220  
Kabir Sethi - TCS New York City Marathon: \$23,361  
Gabe Daly - TCS New York City Marathon: \$22,326

## \$10,000+

Seth Schuster - TCS New York City Marathon: \$18,459  
James Wolf - TCS New York City Marathon: \$17,848  
Steven Amster - United Airlines NYC Half: \$17,145  
Mike Squillante - Jersey City Marathon & Lake Placid Ironman: \$16,852  
Kali Rose - TCS New York City Marathon: \$16,724  
Eliza Moldow - TCS New York City Marathon: \$15,612  
Team Play Hurt - The Speed Project: \$14,581  
Sarah Bracey - TCS New York City Marathon: \$14,114  
Fabiola Hoyo - TCS New York City Marathon: \$13,875  
Hikers for Hope - Four Pass Loop: \$13,375  
Team Cindy Fitzpatrick - ASICS Falmouth Road Race: \$12,028  
Alex Nuffer - Medtronics Twin Cities 10 Mile: \$11,250  
Meaghan Conley - ASICS Falmouth Road Race: \$11,017  
Ayden Nichol - Boston Marathon: \$10,968  
Karen Cotty - Boston Marathon: \$10,465  
Christen Connell - Big Sur International Marathon: \$10,200  
Julia Mitchell - TCS New York City Marathon: \$12,508  
Meaghan O'Brien - TCS New York City Marathon: \$12,101  
Keith Haskel - TCS New York City Marathon: \$10,943  
Bryant Kirkland - TCS New York City Marathon: \$10,410  
Joshua Goldstein - United Airlines NYC Half: \$10,083

► “Being part of Gray Nation Endurance gave every mile a deeper purpose. It meant the world to have the opportunity to honor my brother Archie and carry his memory with me. Training and fundraising for NBTS allowed me to transform grief into action, to turn love and loss into something that could help others facing what our family went through. On marathon day, I felt Archie with me in the crowds, in the city’s energy, and in the moments I needed strength most. It was one of the most healing experiences of my life.”

— Timirose B., 2025 TCS New York Marathon

## FAST FACTS

**\$1.4 Million**  
fundraised by GNE athletes

**33**  
states represented  
by GNE athletes

**346**  
athletes participated  
in 2025

**\$504,128**  
most-ever raised by  
a GNE charity team  
(NYC Marathon)



# Gray Nation Endurance®

## \$7,500+

- Alec Molloy - TCS New York City Marathon: \$9,896
- Christina Macchio - TCS New York City Marathon & United Airlines NYC Half: \$9,537
- Nitin Ramachandran - TCS New York City Marathon & United Airlines NYC Half: \$9,522
- Braden White - TCS New York City Marathon & Hong Kong Marathon: \$9,350
- Timirose Bustamante - TCS New York City Marathon: \$9,222
- Grey Ribbon Runners - RunAPalooza Marathon: \$8,863
- Amanda Devlin - ASICS Falmouth Road Race: \$8,588
- Matthew Carpenter - TCS New York City Marathon: \$8,280
- Team SAM - ASICS Falmouth Road Race: \$8,268
- Chelsea Schwerzler - TCS New York City Marathon: \$8,019
- Lea Hendey - TCS New York City Marathon: \$7,867
- Team BAD K - Royal Parks Half Marathon: \$7,867
- Jim Proferes - TCS New York City Marathon: \$7,680
- Wes Smith - 1,000 Mile Challenge: \$7,575



▲ “Being a part of GNE and participating in the NYC Marathon and The Speed Project has allowed me to find my community and closest friends. When things get tough on my road toward becoming a neurosurgical oncologist, I think about who I am doing it for – my Aunt Imelda, my family, my newfound community, my closest friends. This community has fueled my research endeavors and motivated me to keep pushing forward.”

– Mahalia D., 2025 Speed Project “Play Hurt”

## NATIONAL BRAIN TUMOR RIDE TOP FUNDRAISERS

### TOP TEAMS

1. Lisa’s Riders: \$90,444
2. Dave’s Babe: \$37,230
3. Team Mawn: \$35,344
4. Bike for Ike: \$24,413
5. B.J.’s Team: \$20,785

### TOP INDIVIDUALS

1. Lisa Shapiro: \$29,412
2. Sherri Freedman: \$25,018
3. Bill J. Clarke Jr.: \$12,020
4. Olivia Bianchi: \$11,829
5. Walter H Kuhn: \$10,660

► “I got diagnosed when I had a 2-year-old, and you just start thinking about your life and what you might miss with his life – like his milestones based on your prognosis. I don’t want someone else to go through that, and that’s one of the reasons why I fundraise for NBTS.”

– Josh B., 2025 ASICS Falmouth Road Race



# Donor Honor Roll

Because of compassionate supporters like you, the National Brain Tumor Society continues to directly fund promising brain tumor research, champion the needs of the brain tumor community at the highest levels of government, and deliver support to patients and their care partners.

NBTS commemorates the generosity of this community that collectively fuels a nationwide brain tumor movement to help families feel less alone, to turn advocacy into action, and to translate scientific promise into real progress. We are grateful to each and every one of our community members who financially supported our mission in 2025. Every gift to NBTS fuels our mission and enables our team to carry out our annual goals.

In the pages that follow, we highlight and thank some of our most generous supporters, whose collective impact helped the National Brain Tumor Society achieve life-changing progress in 2025. Each Giving Circle of supporters shows how our individual efforts are magnified when we come together as a community.

- **Visionary Society:** Cumulative lifetime giving of \$250K+
- **Circle of Breakthroughs:** Giving of \$250,000 or more in 2025
- **Circle of Change:** Giving of \$50,000 - \$249,999 in 2025
- **Circle of Progress:** Giving of \$10,000 - \$49,999 in 2025
- **Legacy Society:** A giving community that empowers supporters to leave a lasting imprint on the future of brain tumor research and care through a bequest or other planned gift
- **Catalyst Circle:** Members of the Catalyst Circle have made leadership gifts in support of the Nathanson Family Catalyst Fund for Brain Tumor Research

---

## Donor-Advised Funds

On October 9, 2025, donors across the country came together on DAF Day to celebrate generosity through [donor-advised funds \(DAFs\)](#) — charitable giving accounts that let you set aside money for philanthropy.

This day was a chance for our community to turn intention into action as they joined a movement of people passionate about ending brain tumors once and for all.



◀ “When my sister Amy was diagnosed at just 25, she often spoke about how devastating it was for young people like her to face a terminal diagnosis. Before she died, she said something has to change — that people like her deserve the chance to live long, full lives. ... We chose to give through a donor-advised fund because it helps us be intentional. It allows us to plan ahead, prioritize our giving, and stay committed year after year to the causes that matter most to us. For us, that means making sure Amy’s legacy lives on through progress in brain tumor research.” — *Diana G.*

# Donor Honor Roll

National Brain Tumor Society thanks our donors who gave generously in 2025 to advance our mission.

## VISIONARY SOCIETY:

\$250,000+ cumulative giving since 2008

Anonymous (4)  
AbbVie Pharmaceuticals  
ABC2 - Accelerate Brain Cancer Cure  
Bay Area Angel Adventure  
Bank of America Charitable Foundation  
Bayer Pharmaceuticals  
Carol and Alan J. Bernon Family Foundation  
Brain Cancer Answer Foundation  
Bristol Myers Squibb  
Davina Bruckner  
Steven J. Bryant Foundation  
Dolores Claeys  
Stephen and Ellen Conley  
Robert Lloyd Corkin Charitable Foundation  
Cushman & Wakefield  
Ashley Dabbiere  
Danaher Foundation  
Maben-Davis Family Foundation  
Robert Connor Dawes Foundation  
Howard and Susan Elias and Family  
Fidelity Charitable Gift Fund  
Charles de Ganahl Family Foundation  
GCAR - Global Coalition for Adaptive Research  
Genentech  
Michael and Jamie Goguen  
The Goldhirsh Foundation  
Goldhirsh-Yellin Foundation  
Goldman Sachs Gives  
Tim and Tom Gullikson Foundation  
Steve and Janice Hamill  
Hankin Family Charitable Foundation  
Have A Chance, Inc.  
Invax

Independent Charities Of America  
IQVIA  
Arthur Kern  
Mark and Sandra Kramer  
Steven and Sally Lamb  
Medical Research Charities  
Morgan, Lewis & Bockius LLP  
Mary and Paul Nakayama  
Northern Bank & Trust Company  
The Novikoff Family Foundation  
Novocure  
James Pemberton  
The Lillian Poage Trust  
Rally Foundation for Childhood Cancer Research  
Eileen Roche  
Robert I. Schattner Foundation  
Schering Oncology Biotech  
Schering-Plough Pharmaceuticals, Inc.  
Deborah Newman Sharpe and Today is a Good Day  
Foundation  
StacheStrong  
Stephen and Melanie Sadler  
Students Supporting Brain Tumor Research  
The Stringer Foundation  
Richard Wells  
Wells Fargo Corporate Office  
Faramarz Yousefzadeh  
Zallie Supermarkets, Inc.  
Judi Ross Zuker and Edward Zuker

## CIRCLE OF BREAKTHROUGHS: \$250,000+

Anonymous  
Michael and Jamie Goguen  
Hankin Family Charitable Foundation  
IQVIA

---

*NBTS strives to be accurate in publishing our donor names and their giving levels. If you believe your listing has an error or there has been an omission, please contact NBTS at [donations@braintumor.org](mailto:donations@braintumor.org), as there can be a margin of error when data is entered into our system.*

# Donor Honor Roll

## CIRCLE OF CHANGE: \$50,000 - \$249,999

Anonymous (2)  
Terry and Susan Anderson  
Brain Cancer Answer Foundation  
Davina Bruckner  
Childhood Brain Cancer Research Collaborative  
Chimerix, Inc., a Jazz Pharmaceuticals Company  
Dolores Claeys  
ClearView Healthcare Partners  
Focus Partners  
Howard and Susan Elias and Family  
HFO Foundation  
Imvax  
KM Legacy Foundation  
Bill and Lisa Laskin  
Maben-Davis Family Foundation  
The Nadler Family Charitable Giving Fund  
J. Peter Noonan and Marjorie L. Noonan Foundation Inc.  
North Star Charitable Fund  
The Novikoff Family Foundation  
Novocure  
Stephen and Melanie Sadler  
Servier Pharmaceuticals  
Deborah Newman Sharpe and Today is a Good Day  
Foundation  
StacheStrong  
The Stringer Foundation  
Robert V. Vitale  
Roger Wade  
Richard Wells

## CIRCLE OF PROGRESS: \$10,000 - \$49,999

Anonymous (3)  
Jim and Tintu Akasala  
The Herb Alpert Foundation  
Sara S. and Stuart L. Altman  
Carson and Kari Anderson  
Charles C. Anderson, Sr.  
Harold Anderson  
Geetha Arun  
Brian J. Bennett  
Brian and Erica Birke  
Bristol Fish and Game Association, Inc.  
Allison Brooks  
Christopher Brown

“I support the National Brain Tumor Society because of my best buddy, Brad White, and my dear friend and business partner, Jeff Dropo, who both passed from glioblastoma. No one should have to go through what they went through. Funding research and the science is where we can start to make a difference for better treatments for people like Brad and Jeff. There has to be a breakthrough for a cure, and that is something NBTS is working toward every day.” — Terry A.

▼ “Focus is honored to support the National Brain Tumor Society and the critical work it is doing to advance research, connection, and hope for patients and care partners. For me, and for many of our team members and clients, this cause is deeply personal. By leveraging our people and platform, we believe we can move the needle on awareness and support for this important and impactful organization and the many people it serves.”

— Michael Nathanson, Chairman of Focus, a brain tumor survivor of 25 years, former NBTS Board Chair, and current board member emeritus



▲ From left to right, Gray Nation Endurance® athlete Courtney Cardona, NBTS CEO David Arons, Focus Chairman Michael Nathanson, Gray Nation Endurance athlete James Wolf, and NBTS board member Kabir Sethi

Susan Bucker  
Domenick and Wendy Cama  
Richard E. Capri Foundation  
Michael Cassidy Memorial Fund  
The Cedarwood Family Foundation  
Choate Family Fund  
Coaches Against Cancer, Inc  
Margarita Colon  
Jim Cooper  
Robert Lloyd Corkin Charitable Foundation  
Cortile Gallery, Inc.  
James Covey  
Cravath, Swaine & Moore  
Cynthia Davis  
Theresa Day  
Day One Biopharmaceuticals  
Deep Track Capital, LP  
Samuel Dreyer  
Max Drut  
Sarah Durham and Craig Winer  
Frank and Mary Jean Enderle  
Bonnie Feldman  
Jess Fin Foundation  
Fore Biotherapeutics US

# Donor Honor Roll

## **CIRCLE OF PROGRESS:** *Cont.*

Charles J. Frank Charitable Fund  
Becky and Doug Gladstone  
GCAR - Global Coalition for Adaptive Research  
GLK Foundation  
Google  
Drs. Matthew and Diana Gordon  
Michele Gunnells  
Shawn Guertin  
Amy and Steven Halvorsen  
Mr. and Mrs. John Hamilton  
The Hamilton Company Charitable Foundation  
Diane Hanna  
The Hatman  
Hunter Family Charitable Trust  
In Memory of Matt  
Zinovy Isovich  
Steph James  
Jefferson Health  
Russell W. Jellig  
Jones'n for a Cure  
Julie and Ralph B. Kimball  
Kinetic Partners  
Sophie Barnett Kling  
Mark and Sandra Kramer  
Mr. Walter H. Kuhn and Dr. Beth Alpern  
John and Maria Laffin Trust  
Steven and Sally Lamb  
Laminar Pharmaceuticals SA  
Chauho Magdalen Leung  
Vicki and Gary Lindman  
Ivy & Jonathan Lopez  
Frank and Sarah Macchiarola  
Robert Matthews  
Medical Research Charities  
Medtronic  
Karina Mowbray  
Sara Naison-Tarajano  
Dawn and Michael Nathanson  
Nature Nate's Honey Company  
Chandri Navarro  
Northern Bank & Trust Company  
Oracle  
Parekh Family Foundation  
Christine Parks  
Penn Medicine  
Marta Ann Peterson  
Tim and Kitty Pinch  
Pratt Family Charitable Fund  
Jeremy Rabinovitz and Katherine Savits  
Lido and Leigh Ramadan  
Nadia Ramadan  
Jigar and Kinnary Raythatha  
Roger D. Reading  
Leah Recht  
Regeneron Pharmaceuticals

Samuel Ross  
Rubin Family Charitable Giving Fund  
Ted Rupp  
Emily Savinar-Nogue  
Anthony Scaramucci  
Ms. Averi Schaubman  
Carole Sclafani  
Joseph F. Shapiro  
The Shoals Community Theatre  
Stanford Health Care  
David S. Stone Foundation  
Stryker Corporation  
Students Supporting Brain Tumor Research  
Telix Pharmaceuticals  
Dr. Jeremy Toscano  
Triad Cc  
The Jed Tyler Memorial Fund Inc.  
Ann Ulrich  
University of Maryland School of Medicine  
UT Southwestern Medical Center  
Valero Benefit for Children  
Valero Energy Corporation  
Stephen Walsh  
Brad and Aryn Weinberg  
We Give Foundation  
Kierstan Whitsell  
Christopher Wright  
John Wyman  
Zallie Community Foundation  
Judi Ross Zuker and Edward Zuker

---

## **CATALYST CIRCLE**

*Members of the Catalyst Circle have made leadership gifts in support of the Nathanson Family Catalyst Fund for Brain Tumor Research: [NathansonFund.org](http://NathansonFund.org).*

Martin Bicknell  
The Corkin Family  
Michael and Julie Durbin  
Sarah Durham and Craig Winer  
Michael Goss  
Jeanie and Jim Kirkiles  
Andrew Merken  
Michael and Dawn Nathanson  
Amy Null and Andrew Budson  
Ronald Rubin  
The Sadler Family  
Lowenstein Sandler LLP  
Sentinel Benefits and Financial Group  
Shikiar Family Foundation  
Judi Rotenberg Ross Zuker and Edward Zuker

# The Legacy Society Donor Honor Roll

National Brain Tumor Society's Legacy Society is a giving community that empowers supporters to leave a lasting imprint on the future of brain tumor research and care through a bequest or other planned gift.

A planned gift is more than a donation. It helps to ensure NBTS has the resources needed to drive bold progress for years to come, and it is a powerful expression of commitment to our mission to conquer and cure brain tumors, once and for all.



We extend our heartfelt gratitude to the members who joined the Legacy Society in 2025, as well as to all those who have been part of this generous group by including NBTS in their estate plans. Your visionary support lights the path forward and will make a lasting difference in the lives of countless patients and families for generations to come.

## LEGACY SOCIETY

Anonymous (4)  
Estate of David Akard  
The Jeanette R. Aldi Living Trust  
American United Life Insurance Company  
Elizabeth Jean Apton  
Aurora National Life Assurance Company  
Estate of Patricia K. Bagley  
Estate of Rosemary Bakke  
Rosemary Balazs  
Ruth Frances Bayley and Mathew Paul  
Williamson  
Estate of Gracia P. Berry  
Nancy S. Blakeslee Trust  
Estate of Jane E. Bloom  
Estate of Robert Bloomfield  
Mr. Christopher J. and Mrs. Lynell Bohrer  
Dorothy M. Booth Charitable Trust  
Emily C. Bowman Charitable Remainder  
Annuity Trust  
Brain Tumor Research Trust  
Bert Butterworth  
Estate of Mary Catherine Calisto  
Sharon Conlon  
John Carbahal  
Frank L. Carollo, devoted husband of  
Mary Ellen Carollo  
Estate of Dr. Harriet Character  
Jacqueline Charmaine Naomi Lewis  
Revocable Trust  
Estate of Jim Claeys  
Estate of Elinor Clifford  
Estate of Jean Cooper  
Brian Lee Dankel  
Bonnie Feldman  
Estate of Hilda U. Forchheimer  
Estate of Gary T. Gillan  
Estate of Sandra Gilmour  
Jim Graul  
Estate of Jennifer Griffin  
Estate of Juan Herrera  
Estate of Stanley R. Howard



◀ “My late husband Mathew passed away a day before his 33rd birthday after battling ependymoma for eight years. I decided to become a member of the Legacy Society by including NBTS in my will because it would mean the world to me if any treatments or cures could be found to stop anyone else having to suffer in the same way.”

— Ruth B.

John Foster Hurley  
Estate of Lorene L. Kehler  
Estate of Robert M. Kern  
Estate Of Margaret King  
Jerome A. Klein Irrevocable Trust  
Arthur F. Krueger, Jr.  
Estate of Oscar Leschinsky  
Estate of Rufus Thomas Long  
Sally Long  
Estate of Daisy Lundsten  
Evelyn Luper  
Estate of Lawrence Lynnworth  
John and Joan Marcotte  
Estate of David G. McKinstry  
Estate of Sandra Morrill-Esparza  
Estate of Herman Douglas Morrow  
Nicholas Peter Moulton  
Lois Myers  
Estate of Jenifer L. Newman  
Estate of Carol S. O'Dore  
Mary L. Osborne Trust  
Estate of Loraine E. Perkins  
Pershing LLC  
Estate of Lillian Poage

Estate of Maria R. Podhiny  
Estate of Dorothy M. Ramsey  
Acuna Regli  
Cynthia S. Thompson Trust  
Reliance Trust  
Darla K. Renbarger Irrevocable Trust  
Karen Roberts Turner  
Estate of Karen Sbrockey  
Joseph Andrew Scichilone  
Estate of Michael Selib  
Estate of Linda L. Sellaro  
Estate of Marie Sevitski  
Jeff and Krista Lynn Sinclair  
Estate of Elizabeth Smith  
Susannah Stuart and Russ Lavallee  
Estate of Linda Lee Thunes  
Estate of Clara M. Vernick  
Estate of Lucille C Viator  
Estate of Bruce G. Von Barkhausen  
The Marianne P. Walther Trust  
Estate of Michael Wayne Tolar  
Amanda M. Weig  
Estate of Melanie K. Wellner  
Estate of Howard G. Ziff

# Board of Directors

## OFFICERS

Leah Recht, JD, *Chair*  
Erica Birke, *Vice Chair*  
Frank Macchiarola, JD, *Clerk*  
Mil Parekh, CFP, CPWA, *Treasurer*

## ACTIVE VOTING BOARD MEMBERS

Allison Bishof, CRNA  
Chris Brown, CFA  
Elizabeth Duke, MD  
Sarah Durham  
Adam Hayden  
Jay Nadler  
Jigar Raythatha, MBA  
Kabir Sethi, MBA  
Joohee Sul, MD  
Karen Roberts Turner, JD  
Jonathan Weinberg, JD  
Rabbi Corie Yutkin G.

Bonnie Feldman,  
*Non-Voting Co-Founder*

Al Yung, MD,  
*Non-Voting Honorary Board Member*

## EMERITUS BOARD MEMBERS

Dave Brown  
Rob Burger  
Michael Corkin  
Rob Corrao  
Dave Donabedian  
Sarah Durham  
John Frishkopf  
Eva Galanis, MD  
Richard Genderson  
Ken Grey  
Steve Karol  
Sheila Killeen  
Jeffrey Kolodin (deceased)  
Ryan Lang  
Michael Nathanson, JD, LLM  
Chandri Navarro, JD  
Eric Olson, PhD  
Susan Pannullo, MD  
Thomas Roloff  
Allison Ross  
Dennis Roth  
Steve Sadler  
Liz Salmi  
Cord Schlobohm, DMD  
Charles B. Wilson, MD (deceased)  
Rabbi Eric B. Wisnia (deceased)  
Salo Zelermyer, JD

## Remembering Adam Hayden (1982 - 2025)


Adam lived for nine years with a malignant glioma and made an indelible mark on the brain tumor community through his writing, advocacy, and deeply empathetic leadership. He passed away in December 2025.

Adam served on the NBTS Board of Directors for four years. An energized contributor to the Board's Treatments and Community Committees, as well as NBTS's Research Roundtable Program, Adam brought the patient voice to every conversation, including those with researchers, industry, and members of the FDA. He spearheaded NBTS's Brain Tumor Support Conversations with fellow peer leader and caregiver, Lisa O'Leary. For eight years, Adam showed up on the first Sunday night of each month to bear witness to the experiences of those in the community.

A dedicated father, husband, and friend, Adam leaves behind his wife and caregiver Whitney Hayden, their three sons, Isaac, Noah, and Gideon, and countless other family, friends, and people he's impacted during his life.

**"Align your decisions to your desired quality of life today. Live presently and familiarize yourself with those things that you fear. Consider healing, wellbeing, wholeness, and personal growth that may come through experiencing illness. We each face the same reality, we are, all of us, living while dying. Let's make the most of it."** – Adam Hayden

► "I joined the NBTS Board this year after supporting the organization since the early 1990s when my mother passed away from GBM. I have been encouraged by NBTS's impact on discovering a cure, delivering effective treatments, and advocating for patients and caregivers, and was looking for more ways to support the mission. So this year I also became a donor to the Brain Tumor Investment Fund, which has assembled a very impressive portfolio of promising treatments in a short period of time. When the opportunity arose, I was eager to join the board to deepen my commitment to this very important cause." – Jay Nadler



## FOUNDING BOARD MEMBERS


*National Brain Tumor Society honors the founding members of the board, who came together in 2008 to conquer and cure brain tumors — once and for all.*

Elizabeth Abrahamson	Sharon Lamb
Mary Catherine Calisto, <i>Co-Chair</i>	Stephen Lancot
Michael Corkin	Jan McCormack
G. Bonnie Feldman	Walter Newman
Paul Fisher	Susan Panullo, MD
Nader Ghaffari, <i>Treasurer</i>	Vincent Patrone
Barry Glassman	Cord Schlobohm
Ann Gordon, <i>Clerk</i>	Bryon Sheets
Ken Grey, <i>Vice Chair</i>	Allison Jones Thomson, <i>Co-Chair</i>
Sheila Killeen	Richard B. Ross,
Jeff Kolodin	<i>Brain Tumor Society Co-Founder</i>



“We want to fundraise for NBTS so other people can be as fortunate as we were to have a new medication on the market to treat Leon’s tumor. We want to fund more top-tier research that can lead to newer studies in younger patients and newer medications. I like that NBTS has a specific targeted approach to brain tumors.” — Gabrielle W., Leon’s mom

# Financials



National Brain Tumor Society unrelentingly invests in, mobilizes, and unites our community to discover a cure, deliver effective treatments, and advocate for patients and caregivers. We advance our mission through three interconnected, programmatic strategies: Defeat, Connect, and Change. 85% of funds raised by NBTS go directly to advancing our programs.



# Statement of Financial Position and Statement of Activities

## STATEMENT OF FINANCIAL POSITION

	2025	2024
<b>Assets</b>		
Cash	\$9,719,355	\$8,351,614
Employee Retention Credit Receivable	–	313,754
Investments & Convertible Notes	9,107,958	7,427,415
Pledges Rec	164,700	343,000
Prepays	313,467	321,815
Long-term Assets	420,846	252,872
<b>Total</b>	<b>\$19,726,326</b>	<b>\$17,010,470</b>
<b>Liabilities</b>		
AP & Accrued	\$434,925	\$ 509,434
Research Grants Payable	300,000	250,000
Other Liabilities	391,436	153,388
<b>Total</b>	<b>\$1,126,361</b>	<b>\$912,822</b>
<b>Net Assets</b>		
Without Donor Restrictions	\$12,152,018	\$10,577,674
With Donor Restrictions	6,447,947	5,519,974
<b>Total</b>	<b>\$18,599,965</b>	<b>\$16,097,648</b>
<b>Total Liabilities and Net Assets</b>	<b>\$19,726,326</b>	<b>\$17,010,470</b>






## STATEMENT OF ACTIVITIES

	2025	2024
<b>Revenue</b>		
Events	\$ 8,595,058	\$7,250,797
Grants/Contributions	5,860,169	4,579,107
Bequests	69,640	609,592
Interest, Dividends & Other	606,035	499,961
Donated goods and services	267,781	86,508
<b>Total</b>	<b>\$15,398,683</b>	<b>\$13,025,965</b>
<b>Operating Expenses</b>		
Personnel	\$6,481,671	\$6,337,478
Research Grants	2,502,000	1,905,000
Special Events	1,353,027	1,248,609
Professional Services	794,436	781,707
Travel	354,313	336,140
Systems and IT	388,947	394,683
Other	1,731,090	1,571,812
<b>Total</b>	<b>\$13,605,484</b>	<b>\$12,575,429</b>
<b>Change in Net Assets from Ops</b>	<b>\$1,793,199</b>	<b>\$450,536</b>
<b>Investment Income and Other Revenue</b>	<b>\$709,118</b>	<b>\$360,282</b>
<b>Change in Net Assets</b>	<b>\$2,502,317</b>	<b>\$810,818</b>

National Brain Tumor Society takes great pride in our financial efficiency and accountability. We work to maximize the value of every dollar we receive. The GuideStar Platinum Seal of Transparency is the highest level of recognition offered by the organization. As this designation demonstrates, we are committed to transparent communication and responsible stewardship of donor investment.





-  National Brain Tumor Society
-  natlbraintumorsociety
-  @natlbraintumorsociety
-  @NBTStweets
-  National Brain Tumor Society
-  @braintumor.org
-  @braintumor.org
-  National Brain Tumor Society

55 Chapel Street, Suite 006, Newton, MA 02458 • 617-924-9997

[BrainTumor.org](https://www.BrainTumor.org)